Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Ibrutinib associated invasive fungal diseases in patients with CLL and non-Hodgkin lymphoma: an observational study.

Ruchlemer R, Ben-Ami R, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino SH, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill B, Mulligan SP, Nijland M, Herishanu Y, Benjamini O, Tadmor T, Okamoto K, Arthurs B, Gottesman B, Kater AP, Talha M, Eichhorst B, Korem M, Bogot N, De Boer F, Rowe JM, Lachish T.

Mycoses. 2019 Sep 13. doi: 10.1111/myc.13001. [Epub ahead of print]

PMID:
31520441
2.

Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in a Clinical Practice Setting in China.

Zhang X, Hu J, Hu Y, Huang H, Jin J, Li J, Liu Q, Shao Z, Wang J, Wang Q, Wu D, Huang X.

Clin Ther. 2017 Sep;39(9):1758-1768. doi: 10.1016/j.clinthera.2017.07.013. Epub 2017 Jul 28.

PMID:
28756883
3.

Invasive fungal diseases in patients with acute lymphoid leukemia.

Nicolato A, Nouér SA, Garnica M, Portugal R, Maiolino A, Nucci M.

Leuk Lymphoma. 2016 Sep;57(9):2084-9. doi: 10.3109/10428194.2016.1154957. Epub 2016 Mar 7.

PMID:
26949001
4.

Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.

Kreiniz N, Bejar J, Polliack A, Tadmor T.

Hematol Oncol. 2018 Feb;36(1):349-354. doi: 10.1002/hon.2387. Epub 2017 Feb 3.

PMID:
28156016
5.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.

Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

PMID:
30642819
6.

Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience.

Omer AK, Ziakas PD, Anagnostou T, Coughlin E, Kourkoumpetis T, McAfee SL, Dey BR, Attar E, Chen YB, Spitzer TR, Mylonakis E, Ballen KK.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1190-6. doi: 10.1016/j.bbmt.2013.05.018. Epub 2013 Jun 5.

7.

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.

Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L; French Innovative Leukemia Organization (FILO) CLL group.

Blood. 2018 Apr 26;131(17):1955-1959. doi: 10.1182/blood-2017-11-818286. Epub 2018 Feb 1.

PMID:
29437588
8.

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH.

Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3.

PMID:
30709431
9.

Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).

Iskierka-Jażdżewska E, Puła B, Szeremet A, Hus M, Gołos A, Hołojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Zaucha JM, Warzocha K, Jamroziak K.

Adv Clin Exp Med. 2019 Aug;28(8):1051-1057. doi: 10.17219/acem/99911.

10.

Successful treatment of pulmonary candidiasis and aspergillosis in patient with refractory Hodgkin lymphoma using micafungin - case study and brief literature review.

Barańska M, Kroll-Balcerzak R, Gil L, Rupa-Matysek J, Komarnicki M.

Cent Eur J Immunol. 2017;42(1):111-115. doi: 10.5114/ceji.2016.65893. Epub 2017 May 8.

11.
12.

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators.

N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.

13.

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.

Arthurs B, Wunderle K, Hsu M, Kim S.

Respir Med Case Rep. 2017 Mar 20;21:27-29. doi: 10.1016/j.rmcr.2017.03.011. eCollection 2017.

14.

Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.

Titus-Rains KS, Brown JN, Hammond JM.

J Oncol Pharm Pract. 2018 Oct;24(7):544-549. doi: 10.1177/1078155217718617. Epub 2017 Jul 16. Review.

PMID:
28714377
15.

Prevalence of invasive fungal disease in hematological patients at a tertiary university hospital in Singapore.

Lee SY, Yeo CL, Lee WH, Kwa AL, Koh LP, Hsu LY.

BMC Res Notes. 2011 Feb 28;4:42. doi: 10.1186/1756-0500-4-42.

16.

Pulmonary aspergillosis and aflatoxins in chronic lung diseases.

Ali S, Malik A, Shahid M, Bhargava R.

Mycopathologia. 2013 Oct;176(3-4):287-94. doi: 10.1007/s11046-013-9690-8. Epub 2013 Aug 15.

PMID:
23948964
17.

Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?

Marchesi F, Pimpinelli F, Di Domenico EG, Renzi D, Gallo MT, Regazzo G, Rizzo MG, Gumenyuk S, Toma L, Marino M, Cordone I, Cantonetti M, Liberati AM, Montanaro M, Ceribelli A, Prignano G, Palombi F, Romano A, Papa E, Pisani F, Spadea A, Arcese W, Ensoli F, Mengarelli A.

Int J Mol Sci. 2019 Mar 19;20(6). pii: E1373. doi: 10.3390/ijms20061373.

18.

Aspergillus-PCR in bronchoalveolar lavage for detection of invasive pulmonary aspergillosis in immunocompromised patients.

Buess M, Cathomas G, Halter J, Junker L, Grendelmeier P, Tamm M, Stolz D.

BMC Infect Dis. 2012 Oct 2;12:237. doi: 10.1186/1471-2334-12-237.

19.

Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.

Sun Y, Meng F, Han M, Zhang X, Yu L, Huang H, Wu D, Ren H, Wang C, Shen Z, Ji Y, Huang X.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1117-26. doi: 10.1016/j.bbmt.2015.03.018. Epub 2015 Mar 31.

20.

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators.

Lancet Oncol. 2016 Feb;17(2):200-211. doi: 10.1016/S1470-2045(15)00465-9. Epub 2015 Dec 5.

PMID:
26655421

Supplemental Content

Support Center